First Amendment to Credit Agreement, dated as of October 21, 2019, among PerkinElmer, Inc., PerkinElmer Health Sciences, Inc., PerkinElmer Life Sciences International Holdings, PerkinElmer Global Holdings S. r.l. and PerkinElmer Health Sciences B.V., as Borrowers, Bank of America, N.A. as Administrative Agent, Swing Line Lender and an L/C Issuer, the Lenders party thereto and the other L/C Issuers party thereto, attached hereto as Exhibit 10.2

THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of October 21, 2019 among PERKINELMER, INC., a Massachusetts corporation (the “Company”), PERKINELMER HEALTH SCIENCES, INC., a Delaware corporation (“Health Sciences”), PERKINELMER LIFE SCIENCES INTERNATIONAL HOLDINGS, a company incorporated and registered under the laws of England and Wales with registered number 04418157 (the “UK Borrower”), PERKINELMER GLOBAL HOLDINGS S.À R.L., a private limited liability company (société à responsabilité limitée) incorporated under the laws of Luxembourg, having its registered office at 9, allée Scheffer, L-2520 Luxembourg-city, Luxembourg, registered with the Luxembourg Trade and Companies Register (registre de commerce et des sociétés, Luxembourg) under number B217121 (the “Luxembourg Borrower”), PERKINELMER HEALTH SCIENCES B.V., a private company with limited liability incorporated under the laws of the Netherlands (besloten vennootschap met beperkte aansprakelijkheid) having its official seat (statutaire zetel) in Groningen, and its office at Groningen, Rigaweg 22 (9723TH), registered with the Dutch Trade Register of the Chamber of Commerce under number 02027119 (the “Dutch Borrower”; the Dutch Borrower, together with the Company, Health Sciences, the UK Borrower, and the Luxembourg Borrower, each a “Borrower” and collectively, the “Borrowers”), the Lenders party hereto, and BANK OF AMERICA, N.A., as the Administrative Agent. All capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Credit Agreement (as defined below).

WHEREAS, the Borrowers, the Designated Borrowers from time to time party thereto, the Lenders from time to time party thereto, Bank of America, N.A., as the Administrative Agent, the Swing Line Lender and an L/C Issuer, and the other L/C Issuers party hereto, entered into that certain Credit Agreement, dated as of September 17, 2019 (as amended, restated, amended and restated, supplemented, extended, replaced or otherwise modified from time to time, the “Credit Agreement”);

WHEREAS, the Borrowers have requested that the Credit Agreement be amended as set forth below, subject to the terms and conditions specified in this Amendment; and

WHEREAS, the parties hereto are willing to amend the Credit Agreement, subject to the terms and conditions specified in this Amendment.

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1.Amendment to Credit Agreement. The definition of “Interest Period” in Section 1.01 of the Credit Agreement is amended to read as follows:

“Interest Period” means, as to each Eurocurrency Rate Loan, the period commencing on the date such Eurocurrency Rate Loan is disbursed or converted to or continued as a Eurocurrency Rate Loan and ending on the date one, two, three or six months thereafter (in each case, subject to availability for the interest rate applicable to the relevant currency), as selected by the applicable Borrower in its Committed Loan Notice; provided that: (a) any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day; (b) any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; (c) no Interest Period shall extend beyond the Maturity Date.; and (d) the applicable Borrower may elect in a Committed Loan Notice that the duration of an Interest Period end no earlier than the date seven (7) days prior to, and no later than the date seven (7) days following, the date one, two, three or six months after the disbursement of, or conversion or continuation of, the Eurocurrency Rate Loan requested in such Committed Loan Notice (it being understood and agreed that, notwithstanding

such duration, solely for purposes of determining the Eurocurrency Rate for such Eurocurrency Rate Loan (including for purposes of such determination under Section 2.08(a) and Section 3.03), the Interest Period for such Eurocurrency Rate Loan shall be the date one, two, three or six months after the disbursement of, or conversion or continuation of, the Eurocurrency Rate Loan requested in such Committed Loan Notice).

2.    Condition Precedent. This Amendment shall be effective upon receipt by the Administrative Agent of counterparts of this Amendment duly executed by the Borrowers, the Required Lenders, and the Administrative Agent.

3.    Miscellaneous.

(a)    The Loan Documents and the obligations of the Borrowers thereunder are hereby ratified and confirmed and shall remain in full force and effect according to their terms. This Amendment is a Loan Document.

(b)    Each Borrower represents and warrants that: (i) such Borrower has all requisite power and authority to execute, deliver and perform its obligations under this Amendment; (ii) the execution, delivery and performance by such Borrower of this Amendment have been duly authorized by all necessary corporate or other organizational action, and do not and will not (A) contravene the terms of such Borrower’s Organization Documents, (B) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (1) any Contractual Obligation to which such Borrower is a party or affecting such Borrower or the properties of such Borrower or any of its Subsidiaries, or (2) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Borrower or its property is subject, or (C) violate any Law, except in the cases of clause (b)(ii)(B) and clause (b)(ii)(C) as could not reasonably be expected to have a Material Adverse Effect; (iii) no approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, such Borrower of this Amendment, except as may have been obtained; and (iv) this Amendment has been duly executed and delivered by such Borrower and constitutes a legal, valid and binding obligation of such Borrower, enforceable against such Borrower in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).

(c)    This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or other electronic imagine means shall be effective as delivery of a manually executed counterpart of this Amendment.

(d)    If any provision of this Amendment is held to be illegal, invalid or unenforceable, (i) the legality, validity and enforceability of the remaining provisions of this Amendment shall not be affected or impaired thereby and (ii) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

(e)    THIS AMENDMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AMENDMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

(f)    The terms of Sections 11.14 and 11.15 of the Credit Agreement with respect to submission to jurisdiction, waiver of venue and waiver of jury trial are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first above written.

COMPANY:                PERKINELMER, INC.,

a Massachusetts corporation

By:    /s/ James M. Mock        

Name:    James M. Mock

Title:    Senior Vice President and Chief Financial Officer

BORROWERS:                PERKINELMER HEALTH SCIENCES, INC.,

a Delaware corporation

By:    /s/ John L. Healy                

Name:    John L. Healy

Title:    Vice President and Secretary

a company incorporated under the laws of England and Wales

By:    /s/ John L. Healy                

Name:    John L. Healy

Title:    Director

PERKINELMER GLOBAL HOLDINGS S.À R.L.,

By:    /s/ John L. Healy                

Name:    John L. Healy

Title:    Authorized Signatory

PERKINELMER HEALTH SCIENCES B.V.,

By:    /s/ John L. Healy                

Name:    John L. Healy

Title:    Attorney-in-fact

ADMINISTRATIVE AGENT:        BANK OF AMERICA, N.A.,

as Administrative Agent

By:    /s/ Molly J. Oxford                

Name:    Molly L. Oxford

Title:    Vice President

LENDERS:                BANK OF AMERICA, N.A.,

By:    /s/ Joseph L. Corah                

Name:    Joseph L. Corah

Title:    Director

JPMORGAN CHASE BANK, N.A.,

as a Lender

By:    /s/ David Hyman                

Name:    David Hyman

Title:    Executive Director

WELLS FARGO BANK, NATIONAL ASSOCIATION,

as a Lender

By:    /s/ Sara Barton                

Name:    Sara Barton

Title:    Vice President

MIZUHO BANK, LTD.,

as a Lender

By:    /s/ Donna DeMagistris            

Name:    Donna DeMagistris

Title:    Authorized Signatory

TD BANK, N.A.,

as a Lender

By:    /s/ Shreya Shah                

Name:    Shreya Shah

Title:    Senior Vice President

U.S. BANK NATIONAL ASSOCIATION,

as a Lender

By:    /s/ Michael West                

Name:    Michael West

Title:    Senior Vice President

PNC BANK, NATIONAL ASSOCIATION,

as a Lender

By:    /s/ Steven A. Eberhardt                

Name:    Steven A. Eberhardt

Title:    Vice President

CITIBANK, N.A.,

as a Lender

By:    /s/ Pranjil Gambhir                

Name:    Pranjil Gambhir

Title:    Vice President

HSBC BANK USA, NATIONAL ASSOCIATION,

as a Lender

By:    /s/ Zhiyan Zang                

Name:    Zhiyan Zang

Title:    Vice President